K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer CS Karapetis, S Khambata-Ford, DJ Jonker, CJ O'Callaghan, D Tu, ... New England Journal of Medicine 359 (17), 1757-1765, 2008 | 4456 | 2008 |
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA. 27—a randomized controlled phase III trial PE Goss, JN Ingle, KI Pritchard, MJ Ellis, GW Sledge, GT Budd, ... Journal of clinical oncology 31 (11), 1398, 2013 | 280 | 2013 |
Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group TE Witzig, AM Vukov, TM Habermann, S Geyer, PJ Kurtin, ... Journal of clinical oncology 23 (6), 1103-1108, 2005 | 246 | 2005 |
Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by … M Burnell, MN Levine, JAW Chapman, V Bramwell, K Gelmon, B Walley, ... Journal of Clinical Oncology 28 (1), 77, 2010 | 173 | 2010 |
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268, 2022 | 155 | 2022 |
A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study JJ Biagi, AM Oza, HI Chalchal, R Grimshaw, SL Ellard, U Lee, H Hirte, ... Annals of Oncology 22 (2), 335-340, 2011 | 153 | 2011 |
Effect of metformin vs placebo on weight and metabolic factors in NCIC CTG MA. 32 PJ Goodwin, WR Parulekar, KA Gelmon, LE Shepherd, JA Ligibel, ... Journal of the National Cancer Institute 107 (3), djv006, 2015 | 146 | 2015 |
Phase II study of PX-866 in recurrent glioblastoma MW Pitz, EA Eisenhauer, MV MacNeil, B Thiessen, JC Easaw, ... Neuro-oncology 17 (9), 1270-1274, 2015 | 130 | 2015 |
Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial T Conroy, F Castan, A Lopez, A Turpin, MB Abdelghani, AC Wei, E Mitry, ... JAMA oncology 8 (11), 1571-1578, 2022 | 97 | 2022 |
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA. 27B): a companion analysis of a randomised controlled trial PE Goss, DL Hershman, AM Cheung, JN Ingle, S Khosla, V Stearns, ... The Lancet Oncology 15 (4), 474-482, 2014 | 62 | 2014 |
A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer … MJ Burnell, L Shepherd, K Gelmon, V Bramwell, B Walley, E Vandenberg, ... Cancer Research 72, 2012 | 51 | 2012 |
A randomized phase II study of FOLFOX6/bevacizumab with or without pelareorep in patients with metastatic colorectal cancer: IND. 210, a Canadian Cancer Trials Group Trial DJ Jonker, PA Tang, H Kennecke, SA Welch, MC Cripps, T Asmis, ... Clinical Colorectal Cancer 17 (3), 231-239. e7, 2018 | 49 | 2018 |
The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group MD Seftel, J Kuruvilla, T Kouroukis, V Banerji, G Fraser, M Crump, ... Leukemia & Lymphoma 58 (6), 1358-1365, 2017 | 40 | 2017 |
Comparisons of outcomes of real-world patients with advanced pancreatic cancer treated with FOLFIRINOX versus gemcitabine and nab-paclitaxel: a population-based cohort study N Papneja, A Zaidi, H Chalchal, M Moser, K Tan, C Olson, K Haider, ... Pancreas 48 (7), 920-926, 2019 | 36 | 2019 |
Primary tumor location and survival in the general population with metastatic colorectal cancer S Ahmed, P Pahwa, D Le, H Chalchal, S Chandra-Kanthan, N Iqbal, ... Clinical Colorectal Cancer 17 (2), e201-e206, 2018 | 32 | 2018 |
A phase III adjuvant trial of sequenced EC+ filgrastim+ epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node … MJ Burnell IV, MN Levine, JA Chapman, V Bramwell, T Vandenberg, ... Journal of Clinical Oncology 25 (18_suppl), 550-550, 2007 | 27 | 2007 |
Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA. 21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer AE Lohmann, JAW Chapman, MJ Burnell, MN Levine, E Tsvetkova, ... Breast Cancer Research and Treatment 150, 605-611, 2015 | 24 | 2015 |
Prognoses of T4 breast cancer subsets M El-Tamer, S Hussain, J Weedon, H Chalchal, A Chakrabarti, C Sohn, ... Annals of Surgical Oncology 9, 340-345, 2002 | 23 | 2002 |
Impaired venous hemodynamics in a minority of patients with chronic leg ulcers due to sickle cell anemia. H Chalchal, W Rodino, S Hussain, I Haq, T Panetta, W Solomon, P Gillette, ... VASA. Zeitschrift fur Gefasskrankheiten 30 (4), 277-279, 2001 | 21 | 2001 |
Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study S Ali, J Hendry, D Le, PK Mondal, A Sami, H Chalchal, K Haider, ... Scientific Reports 12 (1), 1068, 2022 | 14 | 2022 |